Attached files

file filename
10-K - FORM 10-K - Chelsea Therapeutics International, Ltd.d287001d10k.htm
EX-10.6 - EMPLOYMENT AGREEMENT - Chelsea Therapeutics International, Ltd.d287001dex106.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Chelsea Therapeutics International, Ltd.d287001dex231.htm
EX-10.3 - 2004 STOCK PLAN, AS AMENDED - Chelsea Therapeutics International, Ltd.d287001dex103.htm
EX-10.17 - MANUFACTURING SERVICES AGREEMENT - Chelsea Therapeutics International, Ltd.d287001dex1017.htm
EXCEL - IDEA: XBRL DOCUMENT - Chelsea Therapeutics International, Ltd.Financial_Report.xls
EX-31.1 - CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 240.13A-14 - Chelsea Therapeutics International, Ltd.d287001dex311.htm
EX-32.1 - CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350 - Chelsea Therapeutics International, Ltd.d287001dex321.htm
EX-31.2 - CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 240.13A-14 - Chelsea Therapeutics International, Ltd.d287001dex312.htm
EX-23.2 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Chelsea Therapeutics International, Ltd.d287001dex232.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Chelsea Therapeutics International, Ltd. (the “Company”) for the period ended December 31, 2011 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, J. Nick Riehle, Vice President, Administration and Chief Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

 

/s/ J. Nick Riehle
J. Nick Riehle
Vice President, Administration and Chief Financial Officer
March 7, 2012